CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
Public ClinicalTrials.gov record NCT04860830. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-3)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Examples include struggling to remember things, or to read a book or pay attention to a movie. Some people have difficulty calculating the right change or planning a trip so that they arrive on time. The purpose of this study is to find out whether a medicine called iclepertin improves learning and memory in people with schizophrenia. Participants are put into two groups randomly, which means by chance. One group takes iclepertin tablets and the other group takes placebo tablets. Placebo tablets look like iclepertin tablets but do not contain any medicine. Participants take a tablet once a day for 26 weeks. In addition, all participants take their normal medication for schizophrenia. During this time, doctors regularly test learning and memory of the participants by use of questionnaires, interviews, and computer tests. The results of the mental ability tests are compared between the groups. Participants are in the study for about 8 months and visit the study site about 14 times. During this time, doctors regularly check participants' health and take note of any unwanted effects.
Study identification
- NCT ID
- NCT04860830
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 609 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 9, 2021 (Actual)
- Primary completion
- Oct 28, 2024 (Actual)
- Completion
- Nov 20, 2024 (Actual)
- Last update posted
- Feb 6, 2026
2021 – 2024
United States locations
- U.S. sites
- 24
- U.S. states
- 12
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Advanced Research Center, Inc. | Anaheim | California | 92805 | — |
| ProScience Research Group | Culver City | California | 90230 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| CNRI - Los Angeles | Pico Rivera | California | 90660 | — |
| Stanford University Medical Center | Stanford | California | 94304 | — |
| Sunwise Clinical Research-Walnut Creek-70166 | Walnut Creek | California | 94596 | — |
| Advanced Medical Research Group Inc | Hollywood | Florida | 33021 | — |
| Accel Research Sites Network | Maitland | Florida | 32751 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Ivetmar Medical Group, LLC | Miami | Florida | 33155 | — |
| Nova Psychiatry Inc. | Orlando | Florida | 32803 | — |
| Synexus Clinical Research-Atlanta-67262 | Atlanta | Georgia | 30328 | — |
| Augusta University | Augusta | Georgia | 30912 | — |
| Center for Behavioral Health, LLC | Gaithersburg | Maryland | 20877 | — |
| Arch Clinical Trials, LLC | St Louis | Missouri | 63141 | — |
| Omaha Insomnia and Psychiatric Services | Omaha | Nebraska | 68144 | — |
| Hassman Research Institute-Berlin-60540 | Berlin | New Jersey | 08009 | — |
| UNC Center for Excellence in Community Mental Health, North Carolina Psychiatric Research Center | Raleigh | North Carolina | 27608 | — |
| Midwest Clinical Research | Dayton | Ohio | 45417 | — |
| Rivus Wellness and Research Institute | Oklahoma City | Oklahoma | 73112 | — |
| Cutting Edge Research Group | Oklahoma City | Oklahoma | 73116 | — |
| Oasis Life Care | State College | Pennsylvania | 16801 | — |
| Ben Taub General Hospital | Houston | Texas | 77030 | — |
| LinQ Research, LLC-Richmond-70076 | Richmond | Texas | 77407 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04860830, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04860830 live on ClinicalTrials.gov.